HomePSTV • NASDAQ
add
Plus Therapeutics Inc
Previous close
$0.51
Day range
$0.50 - $0.53
Year range
$0.16 - $2.31
Market cap
72.00M USD
Avg Volume
33.32M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 1.40M | -4.05% |
Operating expense | 3.44M | 43.64% |
Net income | -4.42M | -53.90% |
Net profit margin | -316.61 | -60.40% |
Earnings per share | -0.04 | 89.19% |
EBITDA | -4.40M | -22.36% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 16.60M | 246.72% |
Total assets | 18.67M | 167.56% |
Total liabilities | 13.62M | 12.05% |
Total equity | 5.05M | — |
Shares outstanding | 137.43M | — |
Price to book | 12.73 | — |
Return on assets | -77.22% | — |
Return on capital | -154.14% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | -4.42M | -53.90% |
Cash from operations | -2.55M | 30.76% |
Cash from investing | 1.30M | 14,511.11% |
Cash from financing | 12.31M | — |
Net change in cash | 11.06M | 399.70% |
Free cash flow | -972.25K | 88.40% |
About
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecular diagnostic service, CNSide®. Wikipedia
Founded
1996
Headquarters
Website
Employees
21
